Version history

{
  "session_id": "sess_SDA-BIOMNI-FINE_MAP-215bc2c6",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\":[{\"title\":\"APOE Region Fine-Mapping with Therapeutic Prioritization\",\"description\":\"Despite statistical complexities from extended LD, APOE remains the highest-priority target for both fine-mapping resolution and therapeutic development. The ε4 allele's OR of 3-4 provides exceptional genetic validation, and active clinical programs (ASOs, gene therapy) demonstrate tractability. Fine-mapping should focus on resolving the functional variants (missense vs regulatory) using allele-specific expression and CRISPR validation. The Skeptic correctly notes that strong LD complicates variant resolution, but the magnitude of genetic effect justifies continued investment in this locus.\",\"target_gene\":\"APOE\",\"composite_score\":0.663,\"evidence_for\":[{\"claim\":\"APOE ε4 demonstrates OR 3-4 for AD, providing exceptional statistical power\",\"pmid\":\"31042675\"},{\"claim\":\"Active ASO clinical program (NCT03957326) demonstrates tractability\",\"pmid\":\"34855572\"},{\"claim\":\"APOE4 homozygosity recognized as distinct genetic form of AD\",\"pmid\":\"34550412\"}],\"evidence_against\":[{\"claim\":\"Extended LD block spans multiple genes, complicating causal variant identification\",\"pmid\":\"23946870\"},{\"claim\":\"Posterior probability misallocation between missense and regulatory variants\",\"pmid\":\"32424313\"}]},{\"title\":\"SORL1 Multi-Ancestry Fine-Mapping and Drug Development\",\"description\":\"SORL1 represents the second-highest priority due to its extracellular sorting receptor architecture amenable to biologics, combined with consistent AD association across ancestries. Multi-ancestry meta-analysis will reduce credible set sizes by leveraging different LD patterns and recombination histories. The target's VPS10P domain structure is characterized, enabling structure-based drug design. Development cost is estimated at $100-200M over 8-12 years, with extracellular localization facilitating antibody-based approaches.\",\"target_gene\":\"SORL1\",\"composite_score\":0.671,\"evidence_for\":[{\"claim\":\"Rare variants cause AD across multiple ancestries including European, East Asian, and African\",\"pmid\":\"31178125\"},{\"claim\":\"Extracellular domain targetable by monoclonal antibodies and small molecules\",\"pmid\":\"29691403\"},{\"claim\":\"Binds APP and affects Aβ production through retromer trafficking\",\"pmid\":\"27085324\"}],\"evidence_against\":[{\"claim\":\"Current sample sizes limit power for fine-mapping in non-European populations\",\"pmid\":\"35050438\"},{\"claim\":\"Effect size for common GWAS variants modest compared to rare coding variants\",\"pmid\":\"30370698\"}]},{\"title\":\"CASS4 Large Credible Set Recognition for Research Prioritization\",\"description\":\"CASS4 exemplifies loci with sparse LD architecture yielding impractically large credible sets (>50 variants). The hypothesis correctly identifies that weak statistical signal (OR ~1.1) combined with limited LD anchors drives poor resolution. However, this hypothesis should be classified as research prioritization rather than therapeutic development. CASS4 is not a viable drug target given the minimal expected clinical impact from modulating a protein with such weak genetic effect. The locus should be deferred until fundamental biology (3-5 years) establishes functional relevance.\",\"target_gene\":\"CASS4\",\"composite_score\":0.520,\"evidence_for\":[{\"claim\":\"CASS4 demonstrates the smallest effect size among top AD loci (OR ~1.1)\",\"pmid\":\"35050438\"},{\"claim\":\"Recombination hotspots flank the gene, creating sparse LD architecture\",\"pmid\":\"35050438\"},{\"claim\":\"Loci with similar effect sizes consistently yield large credible sets\",\"pmid\":\"31754957\"}],\"evidence_against\":[{\"claim\":\"OR ~1.1 insufficient for meaningful clinical intervention\",\"pmid\":\"29691403\"},{\"claim\":\"CASS4 function is poorly characterized; no structural data available\",\"pmid\":\"N/A\"}]},{\"title\":\"BIN1 Allelic Heterogeneity Detected Through Multi-Signal Fine-Mapping\",\"description\":\"BIN1 demonstrates allelic heterogeneity with confirmed secondary signals in conditional analyses, making it a valuable locus for methodological development but not a direct drug target. The BAR domain scaffolding architecture renders it an undruggable PPI target with no feasible small molecule approach within a 10-year horizon. Fine-mapping should apply SuSiE or DAP for multi-signal estimation, and therapeutic efforts should focus on downstream effectors (tau phosphorylation cascades) rather than BIN1 itself. The revised confidence of 0.74 appropriately captures the statistical reality.\",\"target_gene\":\"BIN1\",\"composite_score\":0.497,\"evidence_for\":[{\"claim\":\"Conditional GWAS identified secondary signals at BIN1\",\"pmid\":\"35050438\"},{\"claim\":\"BIN1 primary signal in LD with splicing QTL suggesting causal mechanism\",\"pmid\":\"29507153\"},{\"claim\":\"Allelic heterogeneity confirmed in systematic analyses\",\"pmid\":\"31754957\"}],\"evidence_against\":[{\"claim\":\"BAR domain is flat PPI surface; fundamentally undruggable\",\"pmid\":\"29884772\"},{\"claim\":\"Multiple independent signals suggest different mechanisms; target selection unclear\",\"pmid\":\"31754957\"},{\"claim\":\"BIN1 loss causes viability issues in mice; therapeutic window unclear\",\"pmid\":\"27230451\"}]},{\"title\":\"Multi-Omics Integration with INPP5D/PLCG2 Pathway Focus\",\"description\":\"The hypothesis that multi-omics integration will sharpen credible sets 40-60% lacks theoretical justification and empirical precedent. The target gene selection (INPP5D/PLCG2) is suboptimal—these are not canonical GWAS signal genes for AD. However, PLCG2 P522R variant represents a tractable missense with gain-of-function mechanism that deserves independent consideration regardless of the annotation-prior hypothesis. GARFIELD algorithm benchmarks suggest more modest improvements (~20-30%), and perfect annotation calibration is unrealistic. Development should focus on PLCG2 as a missense target rather than regulatory variant prioritization.\",\"target_gene\":\"PLCG2\",\"composite_score\":0.463,\"evidence_for\":[{\"claim\":\"PLCG2 P522R is a missense variant with gain-of-function mechanism\",\"pmid\":\"30090022\"},{\"claim\":\"Microglia-specific ATAC-seq identifies regulatory variants not captured in blood assays\",\"pmid\":\"31604262\"},{\"claim\":\"H3K27ac marks identify active enhancers in relevant cell types\",\"pmid\":\"31604262\"}],\"evidence_against\":[{\"claim\":\"GARFIELD showed only 20-30% improvement, not 40-60%\",\"pmid\":\"31123356\"},{\"claim\":\"INPP5D not a canonical AD gene; complex splicing patterns complicate targeting\",\"pmid\":\"29507153\"},{\"claim\":\"Model dependence undermines specific effect size claims\",\"pmid\":\"31123356\"}]},{\"title\":\"MEF2C Cell-Type Specific Regulatory Architecture Identification\",\"description\":\"MEF2C represents the highest statistical confidence (0.79) but the lowest therapeutic tractability. As a transcription factor with nuclear localization and DNA-binding interface, it ranks in the bottom 5% of druggable targets by conventional criteria. Loss-of-function causes autism, epilepsy, and intellectual disability, creating extreme toxicity risk. Development should be limited to CRISPR-based approaches for regulatory element replacement rather than small molecule targeting. This hypothesis should be classified as biological insight generation, not drug discovery program initiation. The fine-mapping results will guide research into microglia-specific enhancers but should not trigger conventional therapeutic development.\",\"target_gene\":\"MEF2C\",\"composite_score\":0.433,\"evidence_for\":[{\"claim\":\"MEF2C microglia-specific expression quantitative trait effects confirmed\",\"pmid\":\"29686326\"},{\"claim\":\"MEF2C regulates microglial homeostatic genes in functional studies\",\"pmid\":\"30102359\"},{\"claim\":\"Haploinsufficiency causes severe neurodevelopmental disorder, confirming genetic relevance\",\"pmid\":\"22190034\"}],\"evidence_against\":[{\"claim\":\"Transcription factors rank in bottom 5% of druggable targets\",\"pmid\":\"29884772\"},{\"claim\":\"Loss-of-function causes autism, epilepsy, intellectual disability—extreme toxicity risk\",\"pmid\":\"22190034\"},{\"claim\":\"No hydrophobic pockets for small molecule binding on DNA interface\",\"pmid\":\"29884772\"}]},{\"title\":\"MS4A Brain eQTL Colocalization for Variant Prioritization\",\"description\":\"The hypothesis that brain eQTL colocalization will increase variant-level confidence by a factor of 2.5 is unsupported by theory and benchmarks. The specific factor claim is unjustified given the complexity of colocalization posterior probability calculation. The MS4A cluster is particularly susceptible to eQTL hotspot artifacts where variants affect overall chromatin accessibility, causing false colocalizations with multiple genes. Systematic benchmarks show high false positive rates in colocalization analyses. The locus remains scientifically interesting for understanding regulatory mechanisms but should not drive therapeutic development decisions. Confidence revised to 0.48 reflects these methodological limitations.\",\"target_gene\":\"MS4A6A\",\"composite_score\":0.375,\"evidence_for\":[{\"claim\":\"MS4A demonstrates strong eQTL effects in brain tissue\",\"pmid\":\"35422029\"},{\"claim\":\"Lead GWAS variant rs6591561 in LD with expression-modulating variants\",\"pmid\":\"35050438\"},{\"claim\":\"MS4A expression linked to TREM2-dependent microglial responses\",\"pmid\":\"32044188\"}],\"evidence_against\":[{\"claim\":\"2.5-fold factor has no theoretical basis for universal claim\",\"pmid\":\"33674507\"},{\"claim\":\"eQTL hotspots cause false colocalizations in gene clusters\",\"pmid\":\"33674507\"},{\"claim\":\"High false positive rates documented in systematic colocalization benchmarks\",\"pmid\":\"33674507\"}]}],\"synthesis_summary\":\"This analysis integrates statistical feasibility, therapeutic tractability, and clinical viability to rank seven fine-mapping hypotheses for AD genetics. The key finding is that statistical confidence and therapeutic tractability are orthogonal dimensions—hypotheses with highest confidence (MEF2C at 0.79) face fundamental barriers to drug development (transcription factor target), while lower-confidence hypotheses (APOE at 0.58) represent the most actionable clinical opportunities due to exceptional genetic validation and existing clinical programs. The composite ranking prioritizes SORL1 and APOE as the top two targets based on their balance of scientific merit and development feasibility. The Skeptic's corrections were particularly valuable for H1 (LD complicates resolution, lowering confidence) and H4 (colocalization factor unjustified), while the Expert's druggability assessments correctly identified BIN1, MEF2C, and CASS4 as poor therapeutic targets despite reasonable statistical confidence. These three perspectives converge on a portfolio where fine-mapping resources should prioritize APOE for clinical translation, SORL1 for multi-ancestry validation and drug development, and reserve CASS4, BIN1, and MEF2C as research loci for biological insight rather than therapeutic programs.\\n\\nThe analysis reveals that multi-ancestry meta-analysis (H7) and large credible set recognition (H5) represent the most actionable near-term hypotheses for directing GWAS follow-up resources. Allelic heterogeneity (H3) is confirmed as more prevalent than initially claimed (3-5 may reach 8-10 with larger samples) and requires multi-signal fine-mapping methods. Multi-omics integration (H2) shows promise but the specific 40-60% improvement claim is unsupported; the more modest 20-30% improvements from GARFIELD provide more realistic benchmarks. The field should correct the misconception that strong LD aids fine-mapping—it increases statistical power for association detection but complicates variant-level resolution, requiring functional validation to allocate posterior probability correctly.\",\"knowledge_edges\":[{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"APOE\",\"target_type\":\"gene\",\"relation\":\"primary_target_with_therapeutic_development\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"SORL1\",\"target_type\":\"gene\",\"relation\":\"primary_target_with_therapeutic_development\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"MEF2C\",\"target_type\":\"gene\",\"relation\":\"research_target_no_therapeutic_development\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"CASS4\",\"target_type\":\"gene\",\"relation\":\"research_target_deferred\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"BIN1\",\"target_type\":\"gene\",\"relation\":\"research_target_undruggable\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"PLCG2\",\"target_type\":\"gene\",\"relation\":\"missense_target_independent_of_annotation_hypothesis\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"MS4A6A\",\"target_type\":\"gene\",\"relation\":\"research_target_eQTL_validation_needed\"},{\"source_id\":\"Skeptic_revision\",\"source_type\":\"critique\",\"target_id\":\"H1\",\"target_type\":\"hypothesis\",\"relation\":\"reduced_confidence_from_0.82_to_0.58\"},{\"source_id\":\"Skeptic_revision\",\"source_type\":\"critique\",\"target_id\":\"H4\",\"target_type\":\"hypothesis\",\"relation\":\"reduced_confidence_from_0.74_to_0.48\"},{\"source_id\":\"Expert_feasibility\",\"source_type\":\"feasibility_assessment\",\"target_id\":\"APOE\",\"target_type\":\"gene\",\"relation\":\"high_druggability_viable_clinical_programs\"},{\"source_id\":\"Expert_feasibility\",\"source_type\":\"feasibility_assessment\",\"target_id\":\"SORL1\",\"target_type\":\"gene\",\"relation\":\"medium_high_druggability_extracellular_target\"},{\"source_id\":\"Expert_feasibility\",\"source_type\":\"feasibility_assessment\",\"target_id\":\"MEF2C\",\"target_type\":\"gene\",\"relation\":\"very_low_druggability_transcription_factor\"},{\"source_id\":\"Expert_feasibility\",\"source_type\":\"feasibility_assessment\",\"target_id\":\"BIN1\",\"target_type\":\"gene\",\"relation\":\"very_low_druggability_ppi_target\"},{\"source_id\":\"Bellenguez_2022\",\"source_type\":\"gwascatalog\",\"target_id\":\"BIN1\",\"target_type\":\"gene\",\"relation\":\"secondary_signal_conditional_analysis\"},{\"source_id\":\"Bellenguez_2022\",\"source_type\":\"gwascatalog\",\"target_id\":\"CLU\",\"target_type\":\"gene\",\"relation\":\"secondary_signal_conditional_analysis\"},{\"source_id\":\"Bellenguez_2022\",\"source_type\":\"gwascatalog\",\"target_id\":\"PTK2B\",\"target_type\":\"gene\",\"relation\":\"secondary_signal_conditional_analysis\"},{\"source_id\":\"Nott_2019\",\"source_type\":\"publication\",\"target_id\":\"H2\",\"target_type\":\"hypothesis\",\"relation\":\"supports_microglia_specific_atac_seq_priors\"},{\"source_id\":\"GARFIELD\",\"source_type\":\"method\",\"target_id\":\"H2\",\"target_type\":\"hypothesis\",\"relation\":\"benchmark_shows_20_30_percent_improvement_not_40_60\"},{\"source_id\":\"Karch_2022\",\"source_type\":\"publication\",\"target_id\":\"H1\",\"target_type\":\"hypothesis\",\"relation\":\"evidence_for_apoe_posterior_probability\"},{\"source_id\":\"Ridge_2013\",\"source_type\":\"publication\",\"target_id\":\"H1\",\"target_type\":\"hypothesis\",\"relation\":\"evidence_against_narrow_credible_sets_apoe_region\"}]}",
  "tokens_used": "3681"
}